Insulin analogs are molecularly altered forms of insulin. Compared with human synthetic and animal insulin for treatment of type 2 diabetes, short-acting analogs may offer flexible dosing and convenience, long-acting analogs less nocturnal hypoglycemia, 1 but both at greater cost. 2 Because insulin analogs have become increasingly popular, 3, 4 we examined trends in insulin use, out-of-pocket expenditures, and severe hypoglycemic events among privately insured US adults with type 2 diabetes from 2000 through 2010.
Methods | We conducted a retrospective analysis of data from the Optum Labs Data Warehouse, an administrative claims We defined diabetes according to the Health Plan Employer Data and Information Set criteria and excluded patients with claims for type 1 diabetes in the absence of oral antihyperglycemic medications. First, we calculated the proportion of patients with type 2 diabetes who used any insulin during each year and characterized patients with insulin use through descriptive analyses. Second, we calculated the proportion of patients who obtained each specific insulin type using the Cochran-Armitage test to assess for trends in insulin use. Third, we calculated median out-ofpocket costs associated with each insulin prescription per year (adjusted to 2010 dollars 5 ), comparing costs across years using quantile regression. In addition, among patients with insulin use, we examined age-and sex-adjusted rates of severe hypoglycemic events (hospitalization or emergency department visit with a primary discharge diagnosis of hypoglycemia).
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For all analyses, a 2-sided P value of less than .05 was considered significant. All analyses were performed using SAS statistical software version 9.2 (SAS Institute Inc).
Results | From 2000 through 2010, 123 486 patients filled at least 1 prescription for insulin, comprising 9.7% (95% CI, 9.5%-9.8%) of adults with type 2 diabetes in 2000 and 15.1% (95% CI, 15.0%-15.3%) in 2010 (P = .001). Characteristics of the study sample appear in the (Figure) . Use of animal insulin was less than 1% during all years.
The median out-of-pocket costs per prescription for all types of insulin increased from $19 (interquartile range, $14-$23) in 2000 to $36 (interquartile range, $20-$53) in 2010 (P < .001). A small, nonstatistically significant decline in the rate of severe hypoglycemic events among insulin users was observed (21.1 and 17.7 events per 1000 person-years in 2000 and 2010, respectively, P = .054).
Discussion | Among privately insured adults in the United
States, use of insulin among patients with type 2 diabetes increased from 10% in 2000 to 15% in 2010 in the context of widespread adoption of insulin analogs. Out-of-pocket expenditures increased from a median of $19 to $36. Severe hypoglycemic events declined slightly but this was not statistically significant.
Our study has some limitations. First, we included privately insured patients only; public health care systems may use insulin analogs to a lesser extent. Second, we had no information for total expenditures on insulin and may have underestimated the total cost to the health care system. Third, we could not account for the use or cost of insulin delivery devices (except for prefilled pens). Fourth, we could not identify hypoglycemic events that did not require medical assistance. Although we found a nonsignificant decline in severe hypoglycemia, our analyses may be underpowered and we cannot exclude changes in less severe hypoglycemic events. Fifth, we relied on unpublished working documents describing the database, so there may be some uncertainty regarding the accuracy, completeness, and validity of the data.
We found a large increase in the prevalent use of insulin analogs among privately insured patients with type 2 diabetes. The clinical value of this change is unclear. Types of insulin use among adults with type 2 diabetes who filled ≥1 insulin prescription
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In the panel on the right, error bars indicate interquartile ranges.
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